Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.14

    ▲ −9.00 (−0.98%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Snakk Media — Broadening out the offering

Snakk Media — Broadening out the offering

The benefits of the restructuring initiated in FY17 and continuing through FY18, should be more apparent in FY19 as the business runs for a full year on a lower underlying cost base. The upheaval in mobile advertising markets presents opportunities as well as threats and Snakk is diversifying its offering beyond geolocation in-app advertising to include a broader range of digital and data products. The group is placing shares at NZ$0.0425, raising $144k to ease its tight working capital position.

Fiona Orford-Williams

Written by

Fiona Orford-Williams

Director, TMT

Snakk Media

Broadening out the offering

Media

NXT Company Spotlight

5 November 2018

Price

NZ$0.035

Market cap

NZ$0.6m

Share price graph

Share details

Code

SNK

Listing

NXT

Shares in issue

16.3m

Cash (NZ$m) at 31 March 2018

1.1

Business description

Mobile advertising technology company Snakk Media specialises in engaging consumers. It works to identify and target mobile audiences, whether directly by advertising to mobile devices or indirectly using the mobile consumer data through other channels.

Bull

■

Broadening range of products and services.

■

Strengthened board.

■

Cash injection.

Bear

■

Slower growth of than anticipated.

■

Highly competitive sector.

■

Comparatively small scale.

Analysts

Fiona Orford-Williams

+44 (0)20 3077 5739

Neil Shah

+44 (0)20 3077 5700

Snakk Media coverage is provided through the NXT Research Scheme

The benefits of the restructuring initiated in FY17 and continuing through FY18, should be more apparent in FY19 as the business runs for a full year on a lower underlying cost base. The upheaval in mobile advertising markets presents opportunities as well as threats and Snakk is diversifying its offering beyond geolocation in-app advertising to include a broader range of digital and data products. The group is placing shares at NZ$0.0425, raising $144k to ease its tight working capital position.

Strengthened team

Changes to the operational management team have been made to bring in a new chief commercial officer, whose priorities include expanding the product range within digital media, as well as growing the customer base beyond the core advertising agency clients. The strengthened team is focused on driving product development and ad operations, on tightened financial disciplines, as well as on growing the top line. There remain challenges within the market environment and revenues in H119 for managed services have been below earlier management expectations.

Cash injection

At the end of March 2018, Snakk had a cash position of NZ$1.1m, but the funding of working capital has placed significant restraints on the operation of the business over recent months. Management has been reviewing its capital strategy and at the AGM indicated its intention to raise funds through placing up to 20% of the issued share capital, with two directors participating. Just less than 8% of the issued share capital is being issued for $55k to Yee Industries (with Mr M. Yee to join the board), with the two directors providing $55k and $34k respectively, initially via convertible loans until shareholder approval is obtained.

Valuation: Below last published cash

Having reached NZ$0.10 in June 2018, Snakk’s share price has fallen away to the current lows over the summer and autumn. The group had NZ$1.1m of cash at end March, but this figure is outdated so, at this stage, it is not possible to determine the group’s EV. Given the scale of the group, comparisons to global peers are of limited use but, for context, these currently trade at median multiples of 0.5x EV/sales and 4.3x EV/EBITDA, having fallen sharply in value over the same period.

Historical financials

Year
end

Revenue
(NZ$m)

Gross profit
(NZ$m)

PBT
(NZ$m)

EPS
(c)

EV/gross
profit (x)

EV/Sales
(x)

03/15

9.2

3.9

(4.0)

(25.6)

N/A

N/A

03/16

10.5

6.6

(0.9)

(6.6)

N/A

N/A

03/17

10.6

6.3

(3.2)

(20.2)

N/A

N/A

03/18

10.3

6.0

(0.3)

(1.6)

N/A

N/A

Source: Company accounts

FY19 performance against KOMs

Snakk has now published its performance against target key operating milestones (KOMs) to date for FY19e. The table below shows these in progression.

Exhibit 1: Performance against KOMs

Q119
(%)

Q219
(%)

H119
(%)

FY19 target

(%)

Gross margin

58

57

57

58

Compensation to revenue ratio

47

61

52

34

Impressions delivered to impressions booked

105

102

104

101

% of campaigns delivered to target

98

98

98

98, +/-5

Source: Snakk Media

The third and fourth KOM’s are new this financial year and are more appropriate for assessing the group’s performance. Staff turnover and the click-through rate were dropped, the former as it was inherently volatile given the small base and the latter because the measures that have replaced it are more useful metrics.

The only one of these reported numbers noticeably adrift from target is that for compensation to revenue. This is down to several factors; firstly that revenues from managed services were below those anticipated; secondly that the working capital constraints have been in part behind the delays in bringing new products and services to market; and, thirdly, the compensation bill was swelled by payment of compensation for loss of office to the previous head of sales. Management anticipates that the full-year figure will be 38.2% (provided revenues for the remainder of the year are as now expected), implying a substantial fall in this ratio in H219.

Peer comparison

Snakk’s share price dropped sharply following the KOM updates in early April, falling from NZ$0.27 to NZ$0.09 initially. It then continued to drift, hitting lows of NZ$0.04 in April and May 2018, bouncing to NZ$0.10 in June, then falling away again as the need for cash became more apparent. The year-end cash balance was NZ$1.08m, but, given the time since elapsed, it is not practical to use it to determine the EV. With an FY18 loss per share, the P/E is also not meaningful, rendering peer comparison based on multiples impossible. For context, the quoted companies in the space are trading at the multiples shown below. In June 2018, they were trading at 1.1x EV/sales and 8.6x EV/EBITDA, twice the current levels.

Exhibit 3: Listed peer comparison

Quoted currency

Price

Market cap (m)

EV (m)

EV/sales last (x)

Gross margin last (%)

EV/EBITDA last (x)

P/E last (x)

Taptica

GBP

3.0

192

194

0.9

36.5

6.2

5.9

Criteo

US$

21.3

1,380

924

0.4

35.7

3.4

13.0

SITO Mobile

US$

1.3

31.3

25

0.6

48.3

N/A

N/A

Matomy Media

GBP

20.4

20

52

0.4

21.9

5.2

N/A

Fyber

€

0.2

27

213

1.2

27.3

N/A

N/A

RhythmOne

GBP

1.7

136

143

0.2

42.8

1.5

3.6

Median

0.5

36.1

4.3

5.9

Snakk Media

NZ$

0.03

0.6

N/A

N/A

58.3

N/A

N/A

Source: Thomson Reuters. Note: Prices as at 31 October 2018. Sales and net debt are last reported.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
This report has been commissioned by NZX Limited (“NZX”) and prepared and issued by Edison Investment Research (NZ) Limited (“Edison”). This report has been prepared independently of NZX and does not represent the opinions of NZX. NZX makes no representation in relation to acquiring, disposing of or otherwise dealing in the securities referred to in this report.

All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however neither NZX nor Edison guarantees the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in this report may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Limited (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. This research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison US does not offer or provide personalised advice. This research is distributed in New Zealand by Edison). Edison is the New Zealand subsidiary of Edison Investment Research Limited. Edison is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. The distribution of this document in New Zealand is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the New Zealand Financial Advisers Act 2008 (FAA) (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. Edison publishes information about companies in which we believe our readers may be interested, for informational purposes only, and this information reflects our sincere opinions. This report is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, this report should not be construed as a solicitation or inducement to buy, sell, subscribe, or underwrite any securities referred to in this report. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. Edison has a restrictive policy relating to personal dealing. Edison does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, estimates of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. To the maximum extent permitted by law, NZX, Edison, either of their affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Research: Healthcare

Immunicum — Very busy second half

Immunicum’s second-quarter financial results have been superseded by significant product development and financing news. The agreement of the Phase Ib/II US protocol for ilixadencel with the FDA was an important milestone, but the negotiations on an agreement with a leading global pharmaceutical company for checkpoint inhibitor (CPI) access would be a significant endorsement. The recently proposed c SEK351m combined stock issues will be used to accelerate the manufacturing and potentially the development of ilixadencel, resulting in a cash runway until the end of 2021.

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.